Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.00

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $11.00.

Several brokerages have weighed in on ACRV. HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Acrivon Therapeutics in a research report on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 8th. Finally, Wall Street Zen downgraded Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday.

Acrivon Therapeutics Price Performance

ACRV opened at $2.53 on Thursday. Acrivon Therapeutics has a 12 month low of $1.05 and a 12 month high of $8.00. The stock has a market capitalization of $79.85 million, a P/E ratio of -1.19 and a beta of 1.75. The business has a 50 day simple moving average of $2.15 and a 200-day simple moving average of $1.64.

Acrivon Therapeutics (NASDAQ:ACRV) last released its earnings results on Thursday, November 13th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.10. Research analysts anticipate that Acrivon Therapeutics will post -2.49 EPS for the current year.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nuveen LLC acquired a new stake in shares of Acrivon Therapeutics in the first quarter valued at approximately $27,000. Focus Partners Wealth acquired a new stake in Acrivon Therapeutics during the 3rd quarter valued at $36,000. Quadrature Capital Ltd purchased a new position in Acrivon Therapeutics during the second quarter worth $26,000. Invesco Ltd. acquired a new position in shares of Acrivon Therapeutics in the first quarter worth $72,000. Finally, Algert Global LLC purchased a new stake in shares of Acrivon Therapeutics in the third quarter valued at $81,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.